A prospective study of tubular dysfunction in pediatric patients with beta thalassemia major receiving deferasirox

Pediatric Hematology and Oncology

Volumn 30, Issue 8, 2013, Pages 748-754

  Naderi, Majid ^a   Sadeghi Bojd, Simin ^a   Valeshabad, Ali Kord ^b   Jahantigh, Alireza ^a   Alizadeh, Shaban ^c   Dorgalaleh, Akbar ^c   Tabibian, Shadi ^c   Bamedi, Taregh ^a  

^a ZAHEDAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Beta thalassemia; Deferasirox; Tubular dysfunction

Indexed keywords

BETA 2 MICROGLOBULIN; CREATININE; DEFERASIROX; MAGNESIUM; PHOSPHORUS; POTASSIUM; SODIUM; URIC ACID; BENZOIC ACID DERIVATIVE; IRON CHELATING AGENT; METAL; TRIAZOLE DERIVATIVE;

ADOLESCENT; ARTICLE; BETA 2 MICROGLOBULIN URINE LEVEL; CALCIUM BLOOD LEVEL; CALCIUM URINE LEVEL; CHELATION THERAPY; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG INDUCED DISEASE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERCALCIURIA; HYPERURICOSURIA; KIDNEY TUBULE ABSORPTION; MAGNESIUM BLOOD LEVEL; MAGNESIUM URINE LEVEL; MALE; POTASSIUM BLOOD LEVEL; POTASSIUM URINE LEVEL; PRESCHOOL CHILD; PROSPECTIVE STUDY; PROTEINURIA; SCHOOL CHILD; SIDE EFFECT; SODIUM URINE LEVEL; THALASSEMIA MAJOR; TUBULAR DYSFUNCTION; URIC ACID BLOOD LEVEL; URIC ACID URINE LEVEL; BETA-THALASSEMIA; BLOOD; BLOOD TRANSFUSION; CHEMICALLY INDUCED; CLINICAL TRIAL; DRUG EFFECTS; IRON OVERLOAD; KIDNEY DISEASE; PATHOPHYSIOLOGY; URINE;

ADOLESCENT; BENZOATES; BETA-THALASSEMIA; BLOOD TRANSFUSION; CHILD; CHILD, PRESCHOOL; CREATININE; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; KIDNEY DISEASES; MALE; METALS; PROSPECTIVE STUDIES; TRIAZOLES;

EID: 84885932519     PISSN: 08880018     EISSN: 15210669     Source Type: Journal    
DOI: 10.3109/08880018.2013.823470     Document Type: Article

References (17)

1. Rund D, Rachmilewitz E. Beta-Thalassemia. N Engl J Med. 2005;353(11):1135-1146
2. Musallam KM, Taher AT.Mechanisms of renal disease in beta-Thalassemia. J AmSoc Nephrol: JASN. 2012;23(8):302-1299
3. Cianciulli P, Sollecito D, Sorrentino F, et al. Early detection of nephrotoxic effects in thalassemic patients receiving desferrioxamine therapy. Kidney Int. 1994;46(2):467-470
4. Sumboonnanonda A, Malasit P, Tanphaichitr VS, et al. Renal tubular function in beta-Thalassemia. Pediatr Nephrol. 1998;12(4):280-283
5. Mohkam M, Shamsian BS, Gharib A, et al. Early markers of renal dysfunction in patients with betathalassemiamajor. Pediatr Nephrol. 2008;23(6):971-976
6. Brosnahan G, Gokden N, Swaminathan S. Acute interstitial nephritis due to deferasirox: A case report. Nephrol Dial Transplant. 2008;23(10):3356-3358
7. Lopez-Novoa JM, Quiros Y, Vicente L, et al. New insights into the mechanism of aminoglycoside nephrotoxicity: An integrative point of view. Kidney Int. 2011;79(1):33-45
8. Enas H, Nagla EM. Renal functions in pediatric patients with beta-Thalassemia major: Relation to chelation therapy: Original prospective study. Ital J Pediatr. 2010;36-39
9. Aldudak B, Karabay Bayazit A, Noyan A, et al. Renal function in pediatric patients with betathalassemiamajor. Pediatr Nephrol. 2000;15(1-2):109-112
10. Volti SLI, Gregorio FDI, Schiliro G. Acute changes in renal function associated with deferoxamine therapy. Arch Pediatr AdolescMed. 1990;144(10):1069-1070
11. Economou M, Printza N, Teli A, et al. Renal dysfunction in patients with beta-Thalassemia major receiving iron chelation therapy either with deferoxamine and deferiprone or with deferasirox. Acta Haematol. 2010;123(3):148-152
12. Smolkin V, Halevy R, Levin C, et al. Renal function in children with beta-Thalassemiamajor and thalassemia intermedia. Pediatr Nephrol. 2008;23(10):1847-1851
13. Portman R, Kissane J, Robson A. Use of beta 2 microglobulin to diagnose tubulo-interstitial renal lesions in children. Kidney Int. 1986;30(1):91-98
14. Guder W, Hofmann W. Markers for the diagnosis and monitoring of renal tubular lesions. Clin Nephrol. 1992;38:S3-S7
15. Herrero-Moŕin JD, Málaga S, Ferńandez N, et al. Cystatin C and beta2-microglobulin: Markers of glomerular filtration in critically ill children. Crit Care. 2007;11(3):R59
16. Rheault MN, Bechtel H, Neglia JP, Kashtan CE. Reversible Fanconi syndrome in a pediatric patient on deferasirox. Pediatr Blood Cancer. 2011;56(4):674-676
17. Rafat C, Fakhouri F, Ribeil JA, et al. Fanconi syndrome due to deferasirox. Am J Kidney Dis. 2009;54(5):931-934